Cargando…
A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells
Primary and acquired drug resistance imposes a major threat to achieving optimized clinical outcomes during cancer treatment. Aberrant changes in epigenetic modifications are closely involved in drug resistance of tumor cells. Using BET inhibitor (BETi) resistant leukemia cells as a model system, we...
Autores principales: | Guo, Lei, Li, Jia, Zeng, Hongxiang, Guzman, Anna G., Li, Tingting, Lee, Minjung, Zhou, Yubin, Goodell, Margaret A., Stephan, Clifford, Davies, Peter J. A., Dawson, Mark A, Sun, Deqiang, Huang, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005144/ https://www.ncbi.nlm.nih.gov/pubmed/32029739 http://dx.doi.org/10.1038/s41467-020-14604-6 |
Ejemplares similares
-
BETi induction of mitotic catastrophe: towing the LIN9
por: Gayle, Sylvia S., et al.
Publicado: (2017) -
Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells
por: Saenz, Dyana T., et al.
Publicado: (2017) -
BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells
por: Rossi, Teresa, et al.
Publicado: (2023) -
Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi)
por: Chang Muñoz, Meilen, et al.
Publicado: (2020) -
Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
por: Bian, Benjamin, et al.
Publicado: (2019)